JAC Advance Access originally published online on May 19, 2005
Journal of Antimicrobial Chemotherapy 2005 56(1):172-179; doi:10.1093/jac/dki133
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration
1 Department of Internal Medicine I, Division of Infectious Diseases, Medical University of Vienna, Waehringer Guertel 18–20, A-1090, Vienna ; 2 Department of Internal Medicine II, Intensive Care Unit, Medical University of Vienna, Vienna; 3 Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna; 4 Department of Internal Medicine I, Intensive Care Unit, Medical University of Vienna, Vienna; 5 Institute of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria
Received 17 November 2004; returned 12 January 2005; revised 15 March 2005; accepted 23 March 2005
* Corresponding author. Tel: +43-1-40400-4440; Fax: +49-89-2443-18696; Email: florian.thalhammer{at}meduniwien.ac.at
Objectives: Linezolid is a new antibacterial agent with a broad spectrum of activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., and penicillin-resistant Streptococcus pneumoniae. The aim of this prospective, single-centre, open-label, two-arm study was to investigate the pharmacokinetics of linezolid during continuous venovenous haemofiltration (CVVH) in critically ill patients and to derive a dosage recommendation.
Patients and methods: Twenty anuric ICU patients undergoing CVVH (mean age and body weight 60.7 ± 10.9 years and 86.0 ± 18.0 kg) were included. All patients received linezolid 600 mg intravenously every 12 h. CVVH was performed using highly permeable polysulphone membranes (PSHF 1200, Baxter, Germany and AV 400, Fresenius, Germany). Mean blood flow rate and ultrafiltration rate were 186 ± 15 and 40 ± 8 mL/min, respectively. Post-dilution was performed.
Results: The pharmacokinetics of linezolid in critically ill patients with acute renal failure undergoing CVVH were comparable to healthy subjects and patients without renal impairment. The elimination half-life, total clearance and haemofiltration clearance were 4.3 ± 1.7 h, 9.3 ± 3.5 L/h and 1.9 ± 0.8 L/h, respectively.
Conclusions: Our results showed that linezolid was highly removable by CVVH. These data suggest that a schedule of 600 mg linezolid at least twice daily may also be an appropriate dosing for patients with severe Gram-positive infections undergoing CVVH with both types of membranes.
Keywords: intensive care units , staphylococci , sepsis , acute renal failure
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Plock, C. Buerger, C. Joukhadar, S. Kljucar, and C. Kloft Does Linezolid Inhibit Its Own Metabolism? Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic Patients Drug Metab. Dispos., October 1, 2007; 35(10): 1816 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beer, K. W. Engelhardt, B. Pfausler, G. Broessner, R. Helbok, P. Lackner, C. Brenneis, S. T. Kaehler, A. Georgopoulos, and E. Schmutzhard Pharmacokinetics of Intravenous Linezolid in Cerebrospinal Fluid and Plasma in Neurointensive Care Patients with Staphylococcal Ventriculitis Associated with External Ventricular Drains Antimicrob. Agents Chemother., January 1, 2007; 51(1): 379 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Fiaccadori, U. Maggiore, C. Rotelli, R. Giacosa, E. Parenti, E. Picetti, P. Manini, R. Andreoli, and A. Cabassi Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1402 - 1406. [Abstract] [Full Text] [PDF]
|
|